Updated контакты.txt

CC02 authored
revision 8d436394fe9d0fc4d09a2cd1758c50ec68bb9998
контакты/контакты
# Контакты

![sailor_astolfo_by_osiimi_chan-dbg5nwl.png](images/sailor_astolfo_by_osiimi_chan-dbg5nwl.png)

Если есть вопросы или предложения по добавлению информации отпиши в тред.

**— Почта для связи**
enginecc23@gmail.com


Bicalutamide dose (mg/day)
% PSA decline


10
57


30
73


50
90


100
97


150
97

5α-Reductase inhibitors


5α-Reductase inhibitors (e.g. finasteride, dutasteride) inhibit PSA levels by about 50%[8] by decreasing DHT concentration.


Cyproterone acetate (with and without estrogens)


Trans women aged 18-50 years (median 30 years) treated with 100 mg/day cyproterone acetate had the following PSA response:[9]






























































































Median plasma PSA
Mean plasma PSA
Median urine PSA


Baseline
4 months
12 months
Baseline
4 months
12 months
Baseline
4 months
12 months
Treatment
Subjects
ng/mL
ng/mL
change
ng/mL
change
ng/mL
ng/mL
change
ng/mL
change
ng/mL
ng/mL
change
ng/mL
change
100 mg/day CPA
10
0.333
0.035
-89%
-
-
-
-
-
-
-
10.064
1.124
-89%
-
-
100 mg/day CPA and
17β-estradiol patch twice weekly
15
0.272
0.041
-85%
-
-
-
-
-
-
-
19.885
0.092
-99.5%
-
-
100 mg/day CPA and
100 ug/day oral ethinylestradiol
31
0.296
0.025
-92%
0.01a
-97%a
0.327
0.058
-82%
0.015
-95%
30.138
0.438
-99%
0.251a
-98%a

a Only 17 of the original 31 subjects were analyzed at the 12 month mark.


Reference ranges


The following reference ranges are for serum concentrations. Serum PSA levels may be increased by prostatitis,[10] benign prostatic hyperplasia (BPH),[10] and recent ejaculation[11].





















































Population
Age
Range (ng/mL)
Notes
Cis men[12]
<50
0.3-2.5
90% CI
50-59
0.3-4.7
60-69
0.3-8.3
>70
0.4-17.8
Cis men with
prostate cancer[12]
<50
0.4-163.0
50-59
1.2-372.5
60-69
1.7-253.2
>70
2.3-613.2
Cis men[5]
?
1-2

Cis men with
prostate cancer,
BPH, or prostatitis[5]
?
3-4

Cis women[5][13]
?
0.002
Median
Cis women with
hyperandrogenic
syndromes[5]
?
<0.6